CE-Marked and CLIA-Waived: With the prestigious CEmark and CLIA waiver, the Abbott NMP22 BladderChek Rapid Card sets the goldstandard for diagnostic reliability and user-friendliness. Trusted byhealthcare professionals worldwide, it's the go-to choice for bladder cancerscreening.
FDA-Cleared for Professional and Prescription Home Use:Our rapid card is not just any diagnostic tool; it's an FDA-cleared marveldesigned for both professional point-of-care applications and prescribed homeuse in the United States. It puts the power of early diagnosis directly intothe hands of healthcare providers and patients.
Detecting Bladder Cancer in At-Risk Patients: Bladdercancer doesn't discriminate, and early detection is crucial. The NMP22BladderChek Rapid Card is a lifeline for patients at risk of bladder cancer,providing peace of mind and early intervention when it matters most.
Simple Testing Process: We've simplified the testingprocess to make it accessible to all. Only four drops of urine are needed torun the test, ensuring a hassle-free experience for both patients andhealthcare professionals.
Rapid Results in 30 Minutes: Time is of the essencewhen dealing with cancer. Our rapid card provides results within 30 minutes,enabling healthcare providers to consult with patients during the same visit.It's a game-changer for immediate decision-making.
Complementing Cystoscopy for Greater Confidence: In agroundbreaking study, our NMP22 BladderChek Rapid Card proved its worth as anadjunct marker to cystoscopy. When combined with cystoscopy, it delivered aremarkable 99% sensitivity, boosting confidence in detecting recurrent cancer.It also boasted an impressive 99% NPV overall, making it the ultimatediagnostic combination for ruling out bladder cancer.
Early Detection for Early Intervention: Bladdercancer is best tackled in its early stages. The NMP22 BladderChek Test excelsin early diagnosis and monitoring, working alongside standard diagnosticprocedures. By detecting elevated levels of NMP22 in the urine, it identifiesthe presence of bladder cancer cells, even in the disease's early stages. Thismakes it an indispensable tool for healthcare professionals and patients alike.
No content available
